Log in
Donate

Clinical Trial: SWOG S1613

SWOG S1613

Status: Closed

NCT#03365882

A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification

S1613, Step 3 (optional crossover) is permanently closed to accrual, effective November 30, 2023 at 11:59pm Pacific Time

S1613, Step 2 (randomization) is permanently closed to accrual, effective March 31, 2022.

S1613 is permanently closed to accrual, effective December 31, 2021.

View All Clinical Trials
The Montana Cancer Consortium (MCC) is an independent nonprofit organization whose mission is to bring state-of-the-art cancer care to Montana, Idaho and Wyoming through National Cancer Institute (NCI) sponsored clinical research.

Navigation

About Us

Contact Us

Copyright © Montana Cancer Consortium | All rights reserved